Sandrine Carvès, Muriel Bourgeon-Ghittori, Julien Henry, Rakiba Belkhir, Florent L Besson, Stéphane Levante, Xavier Mariette, Raphaèle Seror
OBJECTIVE: Active Charcot Neuro-osteoarthropathy (CN) is a rare and severe complication of peripheral neuropathy that leads to deformity and disability. No pharmacological treatment is available. Increased osteoclastic activity plays a central role in active CN, particularly via receptor activator of nuclear factor ligand (RANK-L). We aimed to describe clinical, morphological and metabolic imaging effects of denosumab, a fully human monoclonal anti- RANK-L antibody, in active CN. METHODS: In this open-label study, we included all consecutive patients with active refractory CN treated with denosumab in our tertiary center...
December 2021: Joint, Bone, Spine: Revue du Rhumatisme